<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998773</url>
  </required_header>
  <id_info>
    <org_study_id>EMTtf</org_study_id>
    <nct_id>NCT04998773</nct_id>
  </id_info>
  <brief_title>Efficacy of TBS in Treatment Resistant Depression</brief_title>
  <official_title>Efficacy of an Intensive and Spaced Treatment Protocol of Theta Burst Transcranial Magnetic Stimulation in Treatment Resistant Depression: a Randomized Double-blinded Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigacion Sanitaria La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Agency of Medicines and Health Products</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigacion Sanitaria La Fe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Theta Burst Transcranial Magnetic Stimulation (TBS) in dorsolateral prefrontal cortex (DLPFC)&#xD;
      has showed efficacy and safety as an adjuvant strategy for resistant treatment depression in&#xD;
      daily sessions during 4-6 weeks (20-30 sessions). Current investigation in TBS aims to design&#xD;
      intensive treatment protocols so as to achieve earlier responses and higher rates of&#xD;
      efficacy. However, the implementation of TBS in the Public National Health Service requires&#xD;
      cost-effective protocols that ensure and facilitate patients adherence to treatment. The aim&#xD;
      of this trial is to compare the efficacy of a bilateral intensive and spaced protocol of TBS&#xD;
      with a unilateral one and sham stimulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive 22 bilateral sessions of sham/active continuous (right DLPFC) and&#xD;
      intermittent (left DLPFC) TBS during 6 weeks.&#xD;
&#xD;
        -  Weeks 1 and 2: 1 session 5 days a week (10 sessions)&#xD;
&#xD;
        -  Weeks 3,4,5, 6: 1 session 3 days a week (12 sessions)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale 17 items (HDRS-17) at the end of the treatment respect to basal.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Hetero-administered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI-II) respect to basal.</measure>
    <time_frame>2, 6 weeks</time_frame>
    <description>Self-administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS) respect to basal.</measure>
    <time_frame>2, 6 weeks</time_frame>
    <description>Hetero-administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale (YMRS) at the end of the treatment respect to basal.</measure>
    <time_frame>2, 6 weeks</time_frame>
    <description>Hetero-administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Altman Self Rating Mania Scale (ASRM) at the end of the treatment respect to basal.</measure>
    <time_frame>2, 6 weeks</time_frame>
    <description>Self-administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale (CGI) respect to basal.</measure>
    <time_frame>2,6 weeks</time_frame>
    <description>Hetero-administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Scale (HAM-A) respect to basal.</measure>
    <time_frame>2,6 weeks</time_frame>
    <description>Hetero-administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oviedo Sleep Questionnaire (OSQ) respect to basal.</measure>
    <time_frame>2, 6 weeks</time_frame>
    <description>Hetero-administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dimensional Apathy Scale (DAS) respect to basal</measure>
    <time_frame>6 weeks</time_frame>
    <description>Self-administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Screening for Cognitive Impairment por Psychiatry (SCIP) at the end of the treatment respect to basal.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Hetero-administered (versions A and B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey (SF 36) at the end of the treatment respect to basal.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Self-administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment Short Test (FAST) at the end of the treatment respect to basal.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Hetero-administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of Functioning (GAF) at the end of the treatment respect to basal.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Hetero-administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>2 and 6 weeks</time_frame>
    <description>50% reduction in HDRS-17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>2 and 6 weeks</time_frame>
    <description>50% reduction in MADRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission</measure>
    <time_frame>2 and 6 weeks</time_frame>
    <description>HDRS-17&lt;8 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission</measure>
    <time_frame>2 and 6 weeks</time_frame>
    <description>MADRS&lt;11 POINTS</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Resistant Depression, Treatment</condition>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Group Bilateral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 patients, bilateral active TBS stimulation, Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Continuous TBS in right DLPFC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Unilateral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 patients, unilateral left DLPFC active TBS stimulation. Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>32 patients, bilateral sham TBS stimulation. Will receive an intensive-spaced protocol of Sham Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Theta Burst Transcranial Magnetic Bilateral Stimulation</intervention_name>
    <description>TMS protocol of 22 sessions of bilateral active 1800 pulses.</description>
    <arm_group_label>Group Bilateral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Theta Burst Transcranial Magnetic Sham Stimulation</intervention_name>
    <description>TMS protocol of 22 sessions of sham bilateral 1800 pulses.</description>
    <arm_group_label>Group Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Theta Burst Transcranial Magnetic Unilateral Stimulation</intervention_name>
    <description>TMS protocol of 22 sessions of left active 1800 pulses and right sham 1800 pulses.</description>
    <arm_group_label>Group Unilateral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Major Depressive Episode or Depressive phase in Bipolar Disorder DSM-5&#xD;
             criteria.&#xD;
&#xD;
          -  Moderate severity (&gt;14 points in HDRS)&#xD;
&#xD;
          -  2 antidepressant failures or failure in enhancing strategies in the case of bipolar&#xD;
             depression.&#xD;
&#xD;
          -  No changes in treatment 3 week previous to the onset of treatment with TMS.&#xD;
&#xD;
          -  Ability to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any psychiatric comorbidity in axis I or II.&#xD;
&#xD;
          -  Depressive episode with psychotic features.&#xD;
&#xD;
          -  Dysthymia.&#xD;
&#xD;
          -  Treatment with ECT in current depressive episode.&#xD;
&#xD;
          -  Multiresistance (&gt; 6 trials of therapeutic strategies).&#xD;
&#xD;
          -  Suicide risk assessed previous to each session.&#xD;
&#xD;
          -  Patients who missed 2 TMS sessions in a row&#xD;
&#xD;
          -  Neurological comorbidities (epilepsy, Parkinson disease, neurocognitive disorders).&#xD;
&#xD;
          -  Contraindications to TMS: pregnancy, metallic cervical or head implants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pilar Sierra San Miguel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Investigación Sanitaria La Fe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yolanda Cañada, MD</last_name>
    <phone>+34961244154</phone>
    <email>yolanda_canada@iislafe.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Cañada, MD</last_name>
      <phone>+961244154</phone>
      <email>yolanda_canada@iislafe.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska Y, Kennedy SH, Lam RW, Daskalakis ZJ, Downar J. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692. doi: 10.1016/S0140-6736(18)30295-2. Epub 2018 Apr 26. Erratum in: Lancet. 2018 Jun 23;391(10139):e24.</citation>
    <PMID>29726344</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald PB, Chen L, Richardson K, Daskalakis ZJ, Hoy KE. A pilot investigation of an intensive theta burst stimulation protocol for patients with treatment resistant depression. Brain Stimul. 2020 Jan - Feb;13(1):137-144. doi: 10.1016/j.brs.2019.08.013. Epub 2019 Aug 22.</citation>
    <PMID>31477542</PMID>
  </reference>
  <reference>
    <citation>Li CT, Chen MH, Juan CH, Huang HH, Chen LF, Hsieh JC, Tu PC, Bai YM, Tsai SJ, Lee YC, Su TP. Efficacy of prefrontal theta-burst stimulation in refractory depression: a randomized sham-controlled study. Brain. 2014 Jul;137(Pt 7):2088-98. doi: 10.1093/brain/awu109. Epub 2014 May 10.</citation>
    <PMID>24817188</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Investigacion Sanitaria La Fe</investigator_affiliation>
    <investigator_full_name>Pilar Sierra Sanmiguel</investigator_full_name>
    <investigator_title>Principal Investigator, Leader of Mental Health Investigation Group</investigator_title>
  </responsible_party>
  <keyword>TMS</keyword>
  <keyword>iTBS</keyword>
  <keyword>Depression</keyword>
  <keyword>Bipolar depression</keyword>
  <keyword>Antidepressants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

